Identifying CT45A9 as a Potential Cancer Drug Target (G102723680)

Target Name: CT45A9

NCBI ID: G102723680

CT45A9

Identifying CT45A9 as a Potential Cancer Drug Target

Cancer/testis antigen 45A2 (CT45A9) is a protein that is expressed in a variety of tissues, including the breast, lung, and gastrointestinal tract. It is also a potential drug target for cancer treatment.

The identification of CT45A9 as a potential drug target comes from studies that have shown that it is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, it has been shown to play a role in the development and progression of these cancers.

One of the key factors that makes CT45A9 an attractive drug target is its expressed status in a variety of cancer types. This makes it a potential therapy for a wide range of cancers, as it is not limited to a specific type of cancer. Additionally, because it is expressed in many different tissues, it is less likely to cause unintended side effects in other parts of the body.

Another potential mechanism by which CT45A9 may be used as a drug target is its role in cell signaling. Studies have shown that CT45A9 is involved in a variety of signaling pathways, including the NF-kappa pathway and the NF-kappa-B pathway. These pathways are involved in the regulation of cell growth, differentiation, and survival, and are thought to be important for the development and progression of cancer. By targeting CT45A9 with drugs that can inhibit these pathways, it may be possible to prevent cancer growth and progression.

In addition to its potential role as a drug target, CT45A9 is also a potential biomarker for cancer. This is because its expression is often used as a diagnostic marker for various types of cancer, including breast, ovarian, and colorectal cancer. By detecting the expression of CT45A9 in cancer tissue, it may be possible to diagnose the disease at an early stage and inform treatment decisions.

Overall, CT45A9 is a protein that has the potential to be a drug target for cancer treatment. Its expressed status in a variety of cancer types and its role in cell signaling make it an attractive target for drug development. Additionally, its potential use as a biomarker for cancer diagnosis may be an important step in the development of cancer treatments.

Protein Name: Cancer/testis Antigen Family 45 Member A9

The "CT45A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT45A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets